Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody
Platform to be used to generate bi-specific antibodies against immuno-oncology targets
Dec 14, 2015
NEW YORK, Dec. 14, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer today announced new data with a novel bi-specific antibody in a poster presentation at IBC's Antibody Engineering & Therapeutics Conference in San Diego, CA. Immune's poster is titled "Design and Validation of a Novel Tetravalent IgG1-like Bi-Specific Antibody Format" and was on display in the exhibit hall December 8-10, 2015 at the San Diego Convention Center.
In this study, Immune described positive developments with a novel platform for production of tetravalent IgG1-like bi-specific antibodies (bsAb). The prototype bi-specific antibody retained effector functions and mediated redirect killing of target cells by cytokine induced killer T cells demonstrating direct anti-cancer effects in vitro as well as anti-tumor activity and improved survival in vivo in a mouse xenograft model of disseminated leukemia. The newly developed platform will be further used to generate novel bi-specific antibodies against immune-oncology targets.
The poster was presented by Boris Shor, PhD, executive director R&D, Immune Pharmaceuticals and Jean Kadouche, PhD, a scientific co-founder of Immune Pharmaceuticals. This work was developed by a collaborative European consortium (BMC) led by Dr. Kadouche and funded by a European grant.
For poster request, please contact firstname.lastname@example.org
About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporin A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes, bi-specific antibodies nanotherapeutics, including NanomAbs®, and several mid-to late stage small molecules .Immune's non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet™ will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Immune Pharmaceuticals Inc.
For further information: G.John Mohr, Senior Vice-President, Business Development, IMMUNE Pharmaceuticals, Inc., 973.809.5582, email@example.com